Evidence map›Paper›PMID 37520682›Full record

ArticleMolecular therapy. Nucleic acids2023

Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.

Sara H Osum, Eunice I Oribamise, Stanislas M A S Corbière, Mandy Taisto, Tyler Jubenville, Alex Coutts, Mark N Kirstein, James Fisher, Christopher Moertel, Ming Du and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Nucleic acids, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Nonsense-mediated mRNA decay: friend or foe in cancer biology?Cell communication and signaling : CCS · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Sara H OsumMasonic Cancer Center, Department of Pediatrics, University of Minnesota, 2-191 Moos Tower, 515 Delaware Street SE, Minneapolis, MN 55455, USA.
Eunice I OribamiseMasonic Cancer Center, Department of Pediatrics, University of Minnesota, 2-191 Moos Tower, 515 Delaware Street SE, Minneapolis, MN 55455, USA.
Stanislas M A S CorbièreRecombinetics Inc., 3388 Mike Collins Drive, #1, Eagan, MN 55121, USA.
Mandy TaistoRecombinetics Inc., 3388 Mike Collins Drive, #1, Eagan, MN 55121, USA.
Tyler JubenvilleMasonic Cancer Center, Department of Pediatrics, University of Minnesota, 2-191 Moos Tower, 515 Delaware Street SE, Minneapolis, MN 55455, USA.
Alex CouttsRecombinetics Inc., 3388 Mike Collins Drive, #1, Eagan, MN 55121, USA.
Mark N KirsteinMasonic Cancer Center, Department of Pediatrics, University of Minnesota, 2-191 Moos Tower, 515 Delaware Street SE, Minneapolis, MN 55455, USA.
James FisherDepartment of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Room 459, 717 Delaware Street SE, Minneapolis, MN 55414, USA.
Christopher MoertelMasonic Cancer Center, Department of Pediatrics, University of Minnesota, 2-191 Moos Tower, 515 Delaware Street SE, Minneapolis, MN 55455, USA.
Ming DuDepartment of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Bevill Biomedical Research Building Room 432A, 845 19 Street South, Birmingham, AL 35294, USA.
David BedwellDepartment of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Bevill Biomedical Research Building Room 432A, 845 19 Street South, Birmingham, AL 35294, USA.
David A LargaespadaMasonic Cancer Center, Department of Pediatrics, University of Minnesota, 2-191 Moos Tower, 515 Delaware Street SE, Minneapolis, MN 55455, USA.
Adrienne L WatsonRecombinetics Inc., 3388 Mike Collins Drive, #1, Eagan, MN 55121, USA.
University of Minnesota · USRecombinetics (United States) · USUniversity of Alabama at Birmingham · US

Funding

Uncovering treatment targets for peripheral nerve sheath tumor progression in NF1R01NS115438 · NINDS · UNIVERSITY OF MINNESOTA · PI LARGAESPADA, DAVID ANDREW, RATNER, NANCY · 2020 to 2024
$2.9M
NINDS NIH HHS R01 NS115438
6 · The paper itself

Abstract

Neurofibromatosis type 1 (NF1) results from germline mutations in the tumor-suppressor gene

Indexed as

minipigMT: Delivery Strategiesneurofibromatosisnonsense mutationsnonsense suppressionpharmacokineticspreclinical models

Identifiers

PMID37520682
PMCPMC10384610
OpenAlexW4382045051

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.